Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  • Lian Engelen
  • Søren S Lund
  • Isabel Ferreira
  • Lise Tarnow
  • Hans-Henrik Parving
  • Jørgen Gram
  • Winther, Kaj
  • Pedersen, Oluf Borbye
  • Tom Teerlink
  • Rob Barto
  • Coen D A Stehouwer
  • Allan A Vaag
  • Casper G Schalkwijk
Metformin has been reported to reduce a-dicarbonyls, which are known to contribute to diabetic complications. It is unclear whether this is due to direct quenching of a-dicarbonyls or to an improvement in glycemic control. We therefore compared the effects of metformin versus repaglinide, an antihyperglycemic agent with an insulin-secreting mechanism, on the levels of the a-dicarbonyl 3-deoxyglucosone (3DG).
Original languageEnglish
JournalEuropean Journal of Endocrinology
Issue number3
Pages (from-to)371-9
Number of pages9
Publication statusPublished - 2011

    Research areas

  • Carbamates, Confidence Intervals, Deoxyglucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Piperidines

ID: 35312496